Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.20.2
Business (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 11, 2020
USD ($)
shares
Mar. 17, 2020
USD ($)
shares
Feb. 06, 2020
USD ($)
shares
Feb. 03, 2020
USD ($)
shares
Sep. 04, 2019
USD ($)
shares
Jun. 30, 2020
USD ($)
shares
Apr. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
shares
Feb. 29, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
product
Jun. 30, 2019
USD ($)
Nov. 01, 2019
shares
Subsequent Event [Line Items]                                
Sale of stock (in shares) | shares 15,180,000         15,180,000                    
Net proceeds $ 35,400,000         $ 35,400,000                    
Cash and cash equivalents           45,390,553       $ 3,609,438 $ 45,390,553 $ 3,609,438 $ 9,386,865 $ 45,390,553 $ 9,386,865  
Net loss                     13,281,304   $ 6,223,099 34,398,410 13,677,147  
Net cash used in operating activities                           14,294,187 $ 9,838,855  
Accumulated deficit           $ 148,689,027       114,290,617 $ 148,689,027 114,290,617   $ 148,689,027    
Neurological Clinical And Preclinical Stage Compounds                                
Subsequent Event [Line Items]                                
Number of products in development | product                           3    
Over-Allotment Option                                
Subsequent Event [Line Items]                                
Sale of stock (in shares) | shares 1,980,000         1,980,000                    
Armistice Purchase Agreement                                
Subsequent Event [Line Items]                                
Sale of stock (in shares) | shares   1,951,219     1,200,000     1,951,219                
Net proceeds   $ 3,900,000     $ 3,700,000     $ 3,900,000                
Registered Direct Offering                                
Subsequent Event [Line Items]                                
Sale of stock (in shares) | shares     1,306,282           1,306,282              
Net proceeds     $ 5,100,000                          
Armistice | Registered Direct Offering                                
Subsequent Event [Line Items]                                
Sale of stock (in shares) | shares     1,256,282                          
Armistice | Registered Direct Offering | Common stock                                
Subsequent Event [Line Items]                                
Net proceeds                 $ 5,100,000              
Aevi                                
Subsequent Event [Line Items]                                
Loan forgiven       $ 4,100,000           4,100,000            
Pediatric Portfolio                                
Subsequent Event [Line Items]                                
Proceeds from sale of assets                       4,500,000        
Assumption of debt on sale of assets                   15,100,000   15,100,000        
Gain on disposal                       8,000,000.0        
Pediatric Portfolio | AYTU                                
Subsequent Event [Line Items]                                
Liabilities assumed by buyer                   $ 11,000,000.0   $ 11,000,000.0        
Aevi                                
Subsequent Event [Line Items]                                
Consideration transferred, shares issued       $ 15,500,000                        
Shares issued (in shares) | shares       3,900,000                        
Contingent consideration       $ 6,500,000                        
AYTU | Convertible Preferred Stock                                
Subsequent Event [Line Items]                                
Investment (in shares) | shares                   9,800,000   9,800,000       9,800,000
AYTU | Common stock                                
Subsequent Event [Line Items]                                
Net proceeds             $ 12,800,000